Literature DB >> 30097896

Recommendations for the management of rheumatoid arthritis in the Eastern Mediterranean region: an adolopment of the 2015 American College of Rheumatology guidelines.

Thurayya Arayssi1, Manale Harfouche2, Andrea Darzi3, Samar Al Emadi4, Khalid A Alnaqbi5, Humeira Badsha6, Farida Al Balushi7, Carole Dib8, Bassel Elzorkany9, Hussein Halabi10, Mohammed Hammoudeh4, Wissam Hazer11, Basel Masri12, Mira Merashli13, Mohammed Omair14, Nelly Salloum8, Imad Uthman13, Sumeja Zahirovic15, Nelly Ziade16, Raveendhara R Bannuru17, Timothy McAlindon17, Mohamed A Nomier18, Jasvinder A Singh19,20, Robin Christensen21,22, Peter Tugwell23, Holger Schünemann24, Elie A Akl25,26,27.   

Abstract

Clinical practice guidelines can assist rheumatologists in the proper prescription of newer treatment for rheumatoid arthritis (RA). The objective of this paper is to report on the recommendations for the management of patients with RA in the Eastern Mediterranean region. We adapted the 2015 American College of Rheumatology guidelines in two separate waves. We used the adolopment methodology, and followed the 18 steps of the "Guidelines 2.0" comprehensive checklist for guideline development. For each question, we updated the original guidelines' evidence synthesis, and we developed an Evidence Profile (EP) and an Evidence to Decision (EtD) table. In the first wave, we adoloped eight out of the 15 original questions on early RA. The strength changed for five of these recommendations from strong to conditional, due to one or more of the following factors: cost, impact on health equities, the balance of benefits, and harms and acceptability. In the second wave, we adoloped eight out of the original 44 questions on established RA. The strength changed for two of these recommendations from strong to conditional, in both cases due to cost, impact on health equities, balance of benefits and harms, and acceptability. The panel also developed a good practice recommendation. We successfully adoloped 16 recommendations for the management of early and established RA in the Eastern Mediterranean region. The process proved feasible and sensitive to contextual factors.

Entities:  

Keywords:  Adoloped; Guidelines; Management; Recommendations; Rheumatoid arthritis

Mesh:

Substances:

Year:  2018        PMID: 30097896     DOI: 10.1007/s10067-018-4245-5

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  43 in total

1.  Proposal for a new nomenclature of disease-modifying antirheumatic drugs.

Authors:  Josef S Smolen; Désirée van der Heijde; Klaus P Machold; Daniel Aletaha; Robert Landewé
Journal:  Ann Rheum Dis       Date:  2013-09-26       Impact factor: 19.103

2.  [Guidelines 2.0: systematic development of a comprehensive checklist for a successful guideline enterprise].

Authors:  Gian Paolo Morgano; Marina Davoli; Lorenzo Moja; Laura Amato; Eliana Ferroni; Marcello Tirani
Journal:  Recenti Prog Med       Date:  2015-06

3.  GRADE Evidence to Decision (EtD) frameworks for adoption, adaptation, and de novo development of trustworthy recommendations: GRADE-ADOLOPMENT.

Authors:  Holger J Schünemann; Wojtek Wiercioch; Jan Brozek; Itziar Etxeandia-Ikobaltzeta; Reem A Mustafa; Veena Manja; Romina Brignardello-Petersen; Ignacio Neumann; Maicon Falavigna; Waleed Alhazzani; Nancy Santesso; Yuan Zhang; Jörg J Meerpohl; Rebecca L Morgan; Bram Rochwerg; Andrea Darzi; Maria Ximenas Rojas; Alonso Carrasco-Labra; Yaser Adi; Zulfa AlRayees; John Riva; Claudia Bollig; Ainsley Moore; Juan José Yepes-Nuñez; Carlos Cuello; Reem Waziry; Elie A Akl
Journal:  J Clin Epidemiol       Date:  2016-10-03       Impact factor: 6.437

4.  Prevalence of rheumatoid arthritis in persons 60 years of age and older in the United States: effect of different methods of case classification.

Authors:  Elizabeth K Rasch; Rosemarie Hirsch; Ryne Paulose-Ram; Marc C Hochberg
Journal:  Arthritis Rheum       Date:  2003-04

5.  The global burden of rheumatoid arthritis: estimates from the global burden of disease 2010 study.

Authors:  Marita Cross; Emma Smith; Damian Hoy; Loreto Carmona; Frederick Wolfe; Theo Vos; Benjamin Williams; Sherine Gabriel; Marissa Lassere; Nicole Johns; Rachelle Buchbinder; Anthony Woolf; Lyn March
Journal:  Ann Rheum Dis       Date:  2014-02-18       Impact factor: 19.103

6.  Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial.

Authors:  P Verschueren; D De Cock; L Corluy; R Joos; C Langenaken; V Taelman; F Raeman; I Ravelingien; K Vandevyvere; J Lenaerts; E Geens; P Geusens; J Vanhoof; A Durnez; J Remans; B Vander Cruyssen; E Van Essche; A Sileghem; G De Brabanter; J Joly; S Meyfroidt; K Van der Elst; R Westhovens
Journal:  Ann Rheum Dis       Date:  2014-10-30       Impact factor: 19.103

7.  Patients' considerations in the decision-making process of initiating disease-modifying antirheumatic drugs.

Authors:  Ingrid Nota; Constance H C Drossaert; Erik Taal; Mart A F J van de Laar
Journal:  Arthritis Care Res (Hoboken)       Date:  2015-07       Impact factor: 4.794

Review 8.  New therapies for treatment of rheumatoid arthritis.

Authors:  Josef S Smolen; Daniel Aletaha; Marcus Koeller; Michael H Weisman; Paul Emery
Journal:  Lancet       Date:  2007-12-01       Impact factor: 79.321

9.  Cost-effectiveness of abatacept, rituximab, and TNFi treatment after previous failure with TNFi treatment in rheumatoid arthritis: a pragmatic multi-centre randomised trial.

Authors:  Sofie H M Manders; Wietske Kievit; Eddy Adang; Herman L Brus; Hein J Bernelot Moens; Andre Hartkamp; Lidy Hendriks; Elisabeth Brouwer; Henk Visser; Harald E Vonkeman; Jos Hendrikx; Tim L Jansen; Rene Westhovens; Mart A F J van de Laar; Piet L C M van Riel
Journal:  Arthritis Res Ther       Date:  2015-05-22       Impact factor: 5.156

10.  Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study.

Authors:  Maxime Dougados; Karsten Kissel; Philip G Conaghan; Emilio Martin Mola; Georg Schett; Roberto Gerli; Michael Sejer Hansen; Howard Amital; Ricardo M Xavier; Orrin Troum; Corrado Bernasconi; T W J Huizinga
Journal:  Ann Rheum Dis       Date:  2014-01-28       Impact factor: 19.103

View more
  5 in total

Review 1.  A Review of the Prevalence and Unmet Needs in the Management of Rheumatoid Arthritis in Africa and the Middle East.

Authors:  Hani Almoallim; Jamal Al Saleh; Humeira Badsha; Haytham Mohamed Ahmed; Sara Habjoka; Jeanine A Menassa; Ayman El-Garf
Journal:  Rheumatol Ther       Date:  2020-11-23

2.  Contextual differences considered in the Tunisian ADOLOPMENT of the European guidelines on breast cancer screening.

Authors:  Lara A Kahale; Hella Ouertatani; Asma Ben Brahem; Hela Grati; Mohammed Ben Hamouda; Zuleika Saz-Parkinson; Elie A Akl
Journal:  Health Res Policy Syst       Date:  2021-05-13

3.  Tocilizumab-induced granulomatous vasculitis and cutaneous actinomycosis in a patient with rheumatoid arthritis.

Authors:  Justyna Ziandarska; Magdalena Górecka-Sokołowska; Rafał Czajkowski
Journal:  Postepy Dermatol Alergol       Date:  2022-09-01       Impact factor: 1.664

4.  Cross-Cultural Validation of the 5-Item Compliance Questionnaire for Rheumatology to the Arabic Language in Patients with Rheumatoid Arthritis.

Authors:  Mohammed A Omair; Fatima Al Suwayeh; Alanoud Almashaan; Eman Alqurtas; Mohammed K Bedaiwi; Ibrahim Almaghlouth; Abdulaziz Alkahalaf; Haya M Almalaq
Journal:  Patient Prefer Adherence       Date:  2021-06-28       Impact factor: 2.711

5.  Early hydroxychloroquine but not chloroquine use reduces ICU admission in COVID-19 patients.

Authors:  A J J Lammers; R M Brohet; R E P Theunissen; C Koster; R Rood; D W M Verhagen; K Brinkman; R J Hassing; A Dofferhoff; R El Moussaoui; G Hermanides; J Ellerbroek; N Bokhizzou; H Visser; M van den Berge; H Bax; D F Postma; P H P Groeneveld
Journal:  Int J Infect Dis       Date:  2020-09-29       Impact factor: 3.623

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.